BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 12, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Latuda lurasidone: Preliminary Phase III data

Preliminary data from 430 patients in the modified intent-to-treat (mITT) population of the double-blind, Asian Phase III PASTEL trial showed that once-daily 40 mg lurasidone met the primary endpoint of reducing PANSS total score from baseline to week 6 vs. placebo (18.1 vs. 13 points). In the mITT population, the once-daily 80 mg dose of lurasidone non-significantly reduced PANSS total score from baseline to week 6 by 17.5 points. The mITT...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >